pharmaphorum
3,102 FOLLOWERS
Pharmaphorum reports all the latest Pharma news, views, and analysis of healthcare in a rapidly changing world. At Pharmaphorum We are publishers, consultants, and creatives bringing healthcare together. We support our pharmaceutical industry clients through both the reach and reputation of our publication and our consultative and creative capabilities in marketing, medical, communications,..
pharmaphorum
4h ago
Click Therapeutics' digital therapeutic (DTx) for migraine prevention has been cleared by the FDA, becoming the first treatment of its type in the US ..read more
pharmaphorum
4h ago
A Trump executive order aimed at lowering drug prices includes a plan to do away with what industry claims is a flaw in the Inflation Reduction Act ..read more
pharmaphorum
9h ago
A Trump executive order aimed at lowering drug prices includes a plan to do away with what industry claims is a flaw in the Inflation Reduction Act ..read more
pharmaphorum
9h ago
Access to de-identified NHS patient data by researchers based in China is not a security concern, according to UK Biobank ..read more
pharmaphorum
9h ago
J&J chief executive Joaquin Duato has told analysts that tax policy, not tariffs, is the key to increasing pharma manufacturing capacity in the US ..read more
pharmaphorum
12h ago
The EU has approved Eisai and Biogen's Leqembi for a subset of patients with early-stage Alzheimer's disease, more than two years after it was filed ..read more
pharmaphorum
1d ago
Netherlands-based pharma group Norgine has expanded its rare disease portfolio with the acquisition of France's Theravia for an undisclosed sum ..read more
pharmaphorum
1d ago
Sanofi is preparing a phase 3 programme for asthma candidate amlitelimab, despite mixed data in a phase 2 trial ..read more
pharmaphorum
1d ago
Shares in Ironwood fell by a third after it revealed the FDA is insisting on a new phase 3 trial of its short bowel syndrome therapy apraglutide ..read more
pharmaphorum
1d ago
Bristol-Myers Squibb's Camzyos has fallen short in a trial in non-obstructive hypertrophic cardiomyopathy, denting its growth prospects ..read more